Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Sarepta Therapeutics, the maker of a gene therapy for Duchenne …
Read More »Sarepta Therapeutics’ Elevidys faces ‘arduous’ path back to market
